갑상선 유두암에서 BRAFV600E 돌연변이와 연관된 임상병리학적 인자 및 초음파 소견과의 연관성 = Association of BRAFV600E Mutation with Poor Clinical Prognostic Factors and Ultrasonographic Findings in Cases of Papillary Thyroid Carcinoma

다국어 초록 (Multilingual Abstract)

Purpose: This study evaluated the association of the BRAFV600E mutation with known prognostic factors and ultrasonographic characteristics in cases of papillary thyroid carcinoma. Methods: Subjects included 169 patients who received thyroidectomy at Wonju Christian Hospital under the diagnosis of papillary thyroid cancer from February 2010 to October 2011.
Results: Of the total patients who received thyroidectomy, there were 128 cases (75,7%) of BRAFV600E mutation. Neither age nor sex were associated with the BRAFV600E mutation. Tumor size, shape, margin, extrathyroidal extension, central node metastasis and lateral node metastasis were found not to be associated with the BRAFV600E mutation. Tumor calcification, echogenicity and vascularity were also not associated with the mutation.
Conclusion: As debate remains about the association between the BRAFV600E mutation and clincopathologic factors and ultrasonographic characteristics in cases of papillary thyroid carcinoma, further study is needed.

다국어 초록 (Multilingual Abstract)

Purpose: This study evaluated the association of the BRAFV600E mutation with known prognostic factors and ultrasonographic characteristics in cases of papillary thyroid carcinoma. Methods: Subjects included 169 patients who received thyroidectomy at Wonju Christian Hospital under the diagnosis of papillary thyroid cancer from February 2010 to October 2011.
Results: Of the total patients who received thyroidectomy, there were 128 cases (75,7%) of BRAFV600E mutation. Neither age nor sex were associated with the BRAFV600E mutation. Tumor size, shape, margin, extrathyroidal extension, central node metastasis and lateral node metastasis were found not to be associated with the BRAFV600E mutation. Tumor calcification, echogenicity and vascularity were also not associated with the mutation.
Conclusion: As debate remains about the association between the BRAFV600E mutation and clincopathologic factors and ultrasonographic characteristics in cases of papillary thyroid carcinoma, further study is needed.

참고문헌 (Reference)

1 최재영, "유두상 갑상선암에서의 BRAF 변이와 임상병리학적 인자와의 관계" 대한갑상선-내분비외과학회 10 (10): 147-151, 2010

2 윤여규, "갑상선 미세침흡인세포검사 슬라이드에서 BRAF Mutation 검출을 통한 갑상선 유두암의 진단" 대한갑상선-내분비외과학회 10 (10): 12-18, 2010

3 문원진, "Ultrasonography and the Ultrasound-Based Management of Thyroid Nodules: Consensus Statement and Recommendations" 대한영상의학회 12 (12): 1-14, 2011

4 Moon WJ, "Thyroid Study Group, Korean Society of Neuro- and Head and Neck Radiology. Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study" 247 : 762-770, 2008

5 Samaan NA, "The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients" 75 : 714-720, 1992

6 Kebebew E, "The prevalence and prognostic value of BRAF mutation in thyroid cancer" 246 : 466-470, 2007

7 Wellbrock C, "The RAF proteins take centre stage" 5 : 875-885, 2004

8 Kim TY, "The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma" 65 : 364-368, 2006

9 Lang BH, "Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers" 246 : 114-121, 2007

10 Lang BH, "Staging systems for papillary thyroid carcinoma: a review and comparison" 245 : 366-378, 2007

11 Min HS, "S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid" 21 : 748-755, 2008

12 Jo YS, "Relation between BRAFV600E mutation and ultrasonographic findings in papillary thyroid carcinoma" 1 : 60-65, 2008

13 Mercer KE, "Raf proteins and cancer: B-Raf is identified as a mutational target" 1653 : 25-40, 2003

14 Cushing SL, "Prognostic factors in well-differentiated thyroid carcinoma" 114 : 2110-2115, 2004

15 Sebastian SO, "Papillary thyroid carcinoma: prognostic index for survival including the histological variety" 135 : 272-277, 2000

16 Hwang J, "Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction" 194 : W425-W430, 2010

17 Khoo ML, "Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma" 87 : 1814-1818, 2002

18 Tubiana M, "Long-term results and prognostic factors in patients with differentiated thyroid carcinoma" 55 : 794-804, 1985

19 Zerilli M, "Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases" 113 : 936-944, 2008

20 Shaha AR, "Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer" 114 : 393-402, 2004

21 Chung KW, "Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area" 65 : 660-666, 2006

22 Xing M, "BRAF mutation in thyroid cancer" 12 : 245-262, 2005

23 Xing M, "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications" 28 : 742-762, 2007

24 Costa AM, "BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma" 68 : 618-634, 2008

25 Frasca F, "BRAF (V600E) mutation and the biology of papillary thyroid cancer" 15 : 191-205, 2008

26 Guan H, "Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer" 94 : 1612-1617, 2009

27 Kwak JY, "Association of BRAFV600E mutation with poor clinical prognostic factors and US features in korean patients with papillary thyroid microcarcinoma" RADIOLOGICAL SOC NORTH AMERICA 253 (253): 854-860, 200912

28 Mazzaferri EL, "An overview of the management of papillary and follicular thyroid carcinoma" 9 : 421-427, 1999